MXCT - MaxCyte announces preliminary Q4 FY 2022 results below estimates

2023-03-06 18:12:13 ET

• MaxCyte ( NASDAQ: MXCT ) on Monday announced expectations for Q4 and FY 2022 revenue that came in below estimates.
• The company said it anticipated Q4 revenue to be about $12.4M, compared to a consensus figure of $13.14M.
• FY 2022 revenue is expected to be around $44.3M, also below the anticipated consensus of $44.85M.
• MXCT also provided initial 2023 guidance for total revenue growth of 21% to 26% over 2022, including core revenue growth of 20% to 25% over 2022. The consensus revenue estimate is for a Y/Y increase of 28.5%.
• MXCT stock was up 4.3% to $4.60 after hours.
• The company also said it expected its installed base at year end 2022 to be greater than 600 instruments compared to over 500 instruments at year end 2021.

For further details see: